New investor NexPoint led the financing round, which included participation from existing investors Eshelman Ventures, Bristol Myers Squibb, and Kingdon Capital. A convertible note, which was provided by
The new investigational drug, also known as KRP203, is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator. It has been evaluated in Phase I and Phase II trials for
The companies are seeking approval for the antibody to treat adult patients with prurigo nodularis, which is a chronic inflammatory skin disease that causes extreme itch and skin
To be marketed under the proprietary name fylnetra, pegfilgrastim-pbbk was developed in collaboration with Kashiv Biosciences. Fylnetra is used for the treatment of neutropenia, a condition that occurs
Under the collaboration, the company will use its AI drug discovery platform along with Denali Therapeutics’ expertise across the blood-brain barrier (BBB) and neurodegeneration for identifying therapeutically relevant
Anthracyclines just as doxorubicin are the initial treatment of choice for TNBC. Although doxorubicin has reduced breast cancer mortality significantly, it is linked with a dose-dependent cumulative and
Castle Creek is a portfolio company of Paragon Biosciences, which took part in this preferred stock financing. This financing round saw continued support from Fidelity Management & Research
Biliary tract cancer, which is also called as cholangiocarcinoma, is an extremely rare and hard to treat cancer. It impacts more than 2,000 people in the UK annually
Zavegepant nasal spray is claimed to be the only small molecule calcitonin gene-related peptide (CGRP) receptor antagonist in an intranasal formulation for the acute treatment of migraine in
The positive opinion for use of Cosentyx either alone or in combination with methotrexate has been given for the juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA)
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.